Inside CVS Caremark: The Role of PBMs in Drug Costs & Access | SPONSORED

Why It Matters

By demonstrating how scale, technology, and transparency can curb rising drug costs, CVS Caremark’s model influences employer and payer strategies, potentially reshaping the pharmacy benefits market and improving affordability for millions of patients.

Key Takeaways

• CVS Caremark leverages scale to negotiate lower drug prices.
• Specialty pharmacy accounts for half of drug spend despite few patients.
• AI-driven tools boost bio‑similar adoption, saving billions for health plans.
• Transparency models reveal true net medication costs for sponsors.
• Member experience prioritized through digital engagement and utilization management.

Summary

The sponsored Health Affairs podcast features CVS Caremark’s Chief Growth Officer James Marota discussing the evolving role of pharmacy benefit managers (PBMs) in controlling prescription drug costs and improving member access. Marota frames the PBM function around a three‑pillar cost equation—price, product mix, and utilization—highlighting how CVS’s scale and data‑driven approach enable it to negotiate better pricing, steer formulary design toward generics and biosimilars, and manage utilization through care‑management programs. Key insights include the outsized impact of specialty pharmacy, which represents roughly 50% of total drug spend while covering only 2‑3% of members, and the company’s emphasis on transparency, offering sponsors visibility into true net medication costs after rebates. Marota also details how advanced analytics and artificial intelligence identify opportunities for cost savings, such as converting patients to biosimilar therapies. A concrete example cited is a recent biosimilar conversion initiative that achieved over 90% adoption, delivering more than $1.8 billion in savings and reducing co‑pay burdens for members. The discussion also underscores CVS Caremark’s commitment to a member‑centric experience, leveraging digital tools for prior authorizations, real‑time engagement, and provider outreach. The conversation signals that PBMs like CVS Caremark are positioning themselves as strategic partners for employers, health plans, and government entities, offering both cost containment and enhanced member experience amid growing regulatory demands for pricing transparency and value‑based care.

Original Description

THIS SPONSORED PODCAST EPISODE IS BROUGHT TO YOU BY CVS HEALTH.

In this sponsored episode, James Margiotta, Chief Growth Officer at CVS Caremark, joins Health Affairs Publishing's Jessica Bylander to unpack the role of pharmacy benefit managers (PBMs), their impact on prescription drug costs, and the value PBMs bring to the health care system.

James has nearly 35 years of experience driving innovation, operational excellence, and enterprise value across the healthcare system. In his current role, James leads the team responsible for partnering with clients to identify their unique needs and bringing forward strategic solutions to meet their objectives.

Throughout his career at CVS Health, James has scaled businesses across CVS Caremark, CVS Accountable Care, Minute Clinic, Aetna, and CVS Pharmacy — each with its own challenges, cultures, and market dynamics.

James and Jessica's conversation explores how PBMs help employers, health plans, governments, and unions manage rising prescription drug costs while balancing affordability, transparency, and member experience. James explains CVS Caremark’s approach to controlling costs, dives into the growing demands for price transparency, and how artificial intelligence may transform pharmacy benefits and member navigation services.

Health Affairs This Week

Episode

June 3, 2026

★ Episode details: https://share.transistor.fm/s/5ae5563c

★ Additional episodes: http://www.healthaffairs.org